Education
About Us
Working with TipRanks
Follow Us
AbbVie (GB:0QCV)
LSE:0QCV
0QCV Stock Chart & Stats
$226.64
$0.00(0.00%)
At close: 4:00 PM EDT
$226.64
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$164.50 - $244.49
Previous CloseN/A
Volume123.97K
Average Volume (3M)18.06K
Market Cap
$403.92B
Enterprise Value$465.02B
Total Cash (Recent Filing)$5.26B
Total Debt (Recent Filing)$68.87B
Price to Earnings (P/E)96.7
Beta0.49
Next Earnings
Apr 24, 2026EPS Estimate
3.01Next Dividend Ex-DateN/A
Dividend Yield4.77%
Share Statistics
EPS (TTM)2.71
Shares Outstanding1,768,169,100
10 Day Avg. Volume7,013
30 Day Avg. Volume18,063
Financial Highlights & Ratios
PEG Ratio-116.18
Price to Book (P/B)-125.12
Price to Sales (P/S)6.69
P/FCF Ratio22.97
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue7.60
Enterprise Value/Gross Profit10.37
Enterprise Value/Ebitda16.44
Forecast
1Y Price Target
$253.06Price Target Upside11.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)14.54
Revenue Forecast (FY)$67.05B
Bulls Say, Bears Say
Bulls Say
Commercial Execution And Relative ValuationConsistent commercial execution has produced revenue beats and, combined with guided growth, makes the stock appear attractive versus peers at current multiples.
Immunology Franchise MomentumSkyrizi and Rinvoq are reported to be outperforming expectations and have indication expansion opportunities that can support continued revenue growth.
Neuroscience DiversificationStrength in neuroscience products, including Parkinson's disease treatments and Vyalev, provides revenue diversification beyond core immunology drugs.
Bears Say
Competitive Pressure In ImmunologyEmerging competitors, including rival antibodies and potential oral therapies, threaten market share for Skyrizi and Rinvoq and could weigh on long-term growth.
Earnings Quality And Legacy RelianceEarnings beats have been driven in part by legacy products, raising concern about the sustainability and quality of future revenue growth.
Pipeline Visibility And Near-term CatalystsManagement's reduced interim updates and a pipeline focused on early‑stage and life‑cycle programs limit near-term catalysts and increase uncertainty about upcoming growth drivers.
AbbVie News
0QCV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest share price was $164.50 and its highest was $244.49 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $403.92B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Apr 24, 2026 which is in 57 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Feb 04, 2026. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.653 by $0.057.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.64 which represents an annual dividend yield of 4.77%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 3.01.
How many shares outstanding does AbbVie have?
AbbVie has 1,768,169,100 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $2.71 in its last earnings report, beating expectations of $2.653. Following the earnings report the stock price went down -3.494%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in GB:0QCV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$253.06 (11.66% Upside)
$253.06 (11.66% Upside)
Blogger Sentiment
Bullish
GB:0QCV Sentiment 86%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 93%
Bearish news 7%
Bearish news 7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.88%
12-Months-Change
Fundamentals
Return on Equity
9999.00%
Trailing 12-Months
Asset Growth
-0.89%
Trailing 12-Months
Company Description
AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
0QCV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad operational strength: record sales, multiple high‑growth franchises (notably SKYRIZI, RINVOQ, and neuroscience brands), significant R&D and BD investments, and an optimistic 2026 financial outlook (≈9.5% revenue growth, EPS guidance and margin expansion). Headwinds were clearly disclosed — substantial HUMIRA erosion, declines in IMBRUVICA and parts of aesthetics, acquired IPR&D charges compressing near‑term margins, and modest pricing pressure on key immunology assets — but management articulated clear mitigation levers (strong portfolio growth, new approvals, pipeline catalysts, BD additions, and a large free cash flow profile). Overall, positive execution and outlook outweigh the listed challenges.View all GB:0QCV earnings summaries0QCV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
0QCV Stock 12 Month Forecast
Average Price Target
$253.06
▲(11.66% Upside)
Technical Analysis
Options Prices
Currently, No data available
---